Cory Renauer
Value, research analyst, biotech, small-cap

Xenoport: One Door Closed, Two More Opened

Xenoport (NASDAQ:XNPT) is a biopharmaceutical that develops and markets internally discovered candidates with a focus on neurological disorders. Currently the company has a single commercial stage product in the US. Horizant (gabapentin enacarbil) is approved for the treatment of restless legs syndrome (RLS), and postherpetic neuralgia (PHN).

Xenoport shares have been depressed lately, steadily sinking from a high of more than $12.50 in October of 2012, to a recent price of about $4.80. Horizant sales are significant, but hardly enough to bring the company to profitability. In May 2013, failure of its lead candidate to reach its primary endpoint in a Phase 3 trial didn't help any.

Despite the clinical setback, there is a bright glimmer of hope...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details